HTB

Women’s health

Women and HIV: research directions

Smoking during HIV infection may alter the natural history of HPV infection and increase the risk of cervical disease

Hypertension related to HAART in HIV-positive women

Testosterone therapy for women with low androgen levels or body weight

Intrauterine exposure to efavirenz

Antiviral dynamics and sex differences of AZT and 3TC triphosphate concentrations

Women have a greater immunological response to effective HAART

Single-dose nevirapine resistance in over 75% of mothers

Long-term persistence of distinct mutations in genital tract

Nevirapine and MTCT: the single-dose backlash

Is stress associated with CIN progression in HIV-positive women?

Gender differences in rates and reasons for stopping treatment

Maternal health, transmission and fertility

Women: sexual function and relationships

The impact of migration, race and ethnic diversity on healthcare delivery and clinical outcomes in the UK

PK studies reveal significant sex/gender differences

Pediatric studies from 10th CROI

Conference has strong emphasis on women

Reduced testosterone levels in HIV-positive women

European activists highlight importance of gender based research: women experience HIV differently

HAART enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women

In switch study, women twice as likely as men to discontinue HAART due to toxicities

New research points the way for future treatment of women with HIV

Osteopenia seen in testosterone-deficient women with AIDS wasting

HIV-positive women at high risk for pre-cancerous anal lesions

A new women’s research agenda starts to see the light of day

Incidence of invasive cervical cancer in a cohort of HIV-infected women before and after the introduction of HAART

HAART lowers CIN recurrence risk in HIV-positive women

Seroconversion in Kenyan sex-workers linked with reduced HIV-specific immune response

Prevalence and correlates of anaemia in a large cohort of HIV-positive women

Lactic acidosis in pregnant women receiving d4T (stavudine) and ddI (didanosine): EMEA issue statement

Anal HPV infection common in HIV positive and high-risk HIV negative women

HIV and women – overview

US FDA and Bristol-Myers Squibb issue caution for combination HIV therapy with stavudine (d4T) and didanosine (ddI) in pregnant women

HIV infection increases susceptibility to Chlamydia trachomatis pelvic inflammatory disease

Pregnancy does not accelerate progression of HIV-1 infection

Human papillomavirus (HPV) may speed HIV progression

Antiretroviral therapy in children, women and intravenous drug users

Women initiate highly active antiretroviral therapy later than men

Association of vitamin A deficiency With cervical squamous intraepithelial lesions in HIV-positive women

Women and HIV: is it really a biological difference?

Post navigation